drug_type
RELEVANT_DRUG
intervention_type
Biologic; bispecific antibody immunotherapy
drug_description
Etentamig (ABBV-383; TNB-383B) is an intravenous bispecific T-cell–redirecting antibody that binds BCMA on plasma cells and CD3 on T cells to activate cytotoxic T cells and eliminate BCMA+ plasma cells, reducing amyloidogenic light chains.
nci_thesaurus_concept_id
C164668
nci_thesaurus_preferred_term
Etentamig
nci_thesaurus_definition
A T-cell engaging, human, bispecific, immunoglobulin G4 (IgG4) monoclonal antibody (T-BsAb) directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, etentamig binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Binding to low-activating CD3 preferentially activates effector over regulatory T-cells and stimulates minimum cytokine release.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific IgG4 antibody that binds BCMA on plasma cells and CD3 on T cells, creating an immune synapse that activates and redirects cytotoxic T cells to kill BCMA-expressing cells, thereby reducing amyloidogenic light-chain production (with low CD3 activation to limit cytokine release).
drug_name
Etentamig
nct_id_drug_ref
NCT06158854